帕博利珠单抗作为高危肾细胞癌肾切除术后辅助治疗优于酪氨酸激酶抑制剂
该网络Meta分析以安慰剂为共同对照,比较辅助免疫检查点抑制剂与酪氨酸激酶抑制剂在临床非转移性高危肾细胞癌肾切除术后的疗效与安全性,纳入KEYNOTE-564、S-TRAC、ASSURE、PROTECT、ATLAS和SORCE六项试验。与安慰剂相比,帕博利珠单抗(HR 0.68,95%CI 0.51-0.92)和帕唑帕尼800 mg(HR 0.69,95%CI 0.49-0.97)均与更好的无病生存显著相关。与酪氨酸激酶抑制剂相比,帕博利珠单抗与更好的总生存显著相关(HR 0.54,95%CI 0.30-0.97;酪氨酸激酶抑制剂HR 0.93,95%CI 0.83-1.04)。治疗排名分析显示帕博利珠单抗在无病生存和总生存方面均为最佳治疗,且与酪氨酸激酶抑制剂相比任何级别和高级别不良事件的可能性最低。
要点
- 与安慰剂相比,帕博利珠单抗(HR 0.68,95%CI 0.51-0.92)与更好的无病生存显著相关。
- 与酪氨酸激酶抑制剂相比,帕博利珠单抗与更好的总生存显著相关(HR 0.54,95%CI 0.30-0.97)。
- 治疗排名分析显示帕博利珠单抗在无病生存和总生存方面均为最佳,且任何级别和高级别不良事件可能性最低。
核心结论
- 帕博利珠单抗的优越肿瘤学获益及其更好的毒性特征支持其成为肾切除术后高复发风险肾细胞癌患者辅助治疗的新标准。
研究设计与样本
- 网络Meta分析,以安慰剂为共同对照,纳入六项试验(KEYNOTE-564、S-TRAC、ASSURE、PROTECT、ATLAS和SORCE)。
主要发现
- 与安慰剂相比,帕博利珠单抗(HR 0.68,95%CI 0.51-0.92)和帕唑帕尼800 mg(HR 0.69,95%CI 0.49-0.97)均与更好的无病生存显著相关。
- 与酪氨酸激酶抑制剂相比,帕博利珠单抗(HR 0.54,95%CI 0.30-0.97)与更好的总生存显著相关;酪氨酸激酶抑制剂HR 0.93,95%CI 0.83-1.04。
- 治疗排名分析显示帕博利珠单抗在无病生存和总生存方面均为最佳治疗,且与酪氨酸激酶抑制剂相比任何级别和高级别不良事件的可能性最低。
临床怎么用
- 对于肾癌复发高风险患者,术后帕博利珠单抗治疗提供最佳风险/获益比。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We determined the oncologic outcomes and safety profiles of adjuvant immune checkpoint inhibitors (ICIs) compared to adjuvant tyrosine kinase inhibitors (TKIs) in patients at high risk after nephrectomy for clinically nonmetastatic renal cell carcinoma (RCC). Network meta-analyses were conducted for disease-free survival (DFS), overall survival (OS), and adverse events (AEs) with placebo as the common comparator arm. Six trials (KEYNOTE-564, S-TRAC, ASSURE, PROTECT, ATLAS, and SORCE) were included in our analysis. Compared to placebo, both pembrolizumab (hazard ratio [HR] 0.68, 95% confidence interval [CI] 0.51-0.92) and pazopanib 800 mg (HR 0.69, 95% CI 0.49-0.97) were significantly associated with better DFS. Adjuvant pembrolizumab (HR 0.54, 95% CI 0.30-0.97) was significantly associated with better OS compared to TKIs (HR 0.93, 95% CI 0.83-1.04). Analysis of treatment ranking revealed that pembrolizumab was the best treatment with regard to both DFS and OS and had the lowest likelihood of any-grade and high-grade AEs in comparison to TKIs. The superior oncologic benefit of pembrolizumab and its better toxicity profile support it as the new standard of care in the adjuvant setting for nephrectomy patients at high risk of RCC relapse. PATIENT SUMMARY: For patients with kidney cancer at high risk of relapse after surgical removal of their kidney, postoperative therapy with the immune checkpoint inhibitor pembrolizumab offers the best risk/benefit ratio.
引用
- Laukhtina E, Quhal F, Mori K, et al. Pembrolizumab outperforms tyrosine kinase inhibitors as adjuvant treatment in patients with high-risk renal cell carcinoma after nephrectomy. Eur Urol Oncol. 2022. PMID: 34992006. doi:10.1016/j.euo.2021.12.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。